26 Oct 2017

The study of “Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses” is the first to demonstrate a significan...

Please reload

Recent Posts

Please reload

Archive